Navigation Links
Rheumatoid Arthritis New Major Clinical Target After Mesoblast Obtains Positive Results in Inflammatory Arthritis
Date:7/23/2012

MELBOURNE, Australia, July 23, 2012 /PRNewswire/ --

Key Points:

* Intravenous injection of Mesenchymal Precursor Cells (MPCs) resulted in selective migration to inflamed joints and lymph nodes in a sheep model of Rheumatoid Arthritis (RA)

* A single intravenous injection of allogeneic, or "off-the-shelf", MPCs significantly reduced synovial tissue levels of TNF-alpha, IL-6, and IL-17, and reduced mononuclear cell infiltration

* Reduced cytokine and inflammatory cell levels were accompanied by significant reduction in pathology severity scores and synovial hyperplasia

* MPCs may have a mechanism of action that is unique from other biological therapies by shutting down multiple cytokine pathways simultaneously

* MPCs could be a safe, first line therapy to induce sustained improvement of joint inflammation in RA

* Phase 2 clinical trial in RA expected to commence Q4 2012

* RA is the second clinical indication, after type 2 diabetes, to be targeted using Mesoblast's intravenous product formulation

Melbourne, Australia; 24 July 2012: Regenerative medicine company Mesoblast Limited (ASX:MSB) today announced positive results in a large animal model of Rheumatoid Arthritis (RA) following a single intravenous injection of its proprietary allogeneic, or "off-the-shelf", immunomodulatory adult Mesenchymal Precursor Cells (MPCs).

Mesoblast Chief Executive Professor Silviu Itescu said that the results indicated that the Company's immunomodulatory MPCs may have a mechanism of action that is unique from other biological therapies by shutting down multiple cytokine pathways simultaneously, and that this could become a first line treatment with a superior and sustained benefit on reducing inflammation and destruction of joints in people suffering from severe RA.

RA is an autoimmune disease driven and perpetuated by pro-inflammatory cytokines such as TNF-alpha, IL-6, and IL-17. Treatments targeting
'/>"/>

SOURCE Mesoblast Ltd
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Lilly and Incytes Oral JAK1 and JAK2 Inhibitor, Baricitinib, Showed Positive Results in Phase IIb Study in Patients with Active Rheumatoid Arthritis
2. Flexions Lead Osteoarthritis Drug Candidate Demonstrates Significant, Prolonged Improvement in Pain and Function in Phase 2 Trial
3. Innovations for Osteoarthritis, Sports Injuries and Orthopedic Practices
4. Arthritis Associates of South Florida Acquires Access to Patient Health History Faster with Digital Pen Technology from Anoto and NextGen Healthcare
5. United States Market for Psoriatic Arthritis Pharmacotherapy
6. TSI Healthcare adds Arthritis and Rheumatology Associates of Palm Beach to growing list of Rheumatology Clients
7. Data from Study of Elderly Depressed Patients are Reported for Investigational Compound Lu AA21004 on Symptoms of Major Depressive Disorder (MDD)
8. Omega Laboratories Applauds the Adoption of Enzyme Immunoassay (EIA) by Major Hair Testing Laboratories
9. Tetra Discovery Partners Receives Major NIH Award To Develop New Alzheimers Drug
10. LIVE VIA SATELLITE: Physician Demonstrates New Medical Technology to Combat Back Pain without Major Surgery
11. First Patients Dosed in Ib Phase of Neuralstems NSI-189 Trial in Major Depressive Disorder
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... and VANCOUVER , July ... ) announced today that it will report its second ... Company management will host a conference call and live ... overview of financial results, clinical development programs and a ... webcast, log on to the Investor Relations page of ...
(Date:7/30/2015)... 2015  Amgen (NASDAQ: AMGN ) today announced the ... of Warburg Pincus LLC, to the Amgen Board of Directors. ... Hassan and the deep, global experience he brings in ... A. Bradway , chairman and chief executive officer of Amgen. "Fred,s ... Amgen well." Mr. Hassan has been Partner and ...
(Date:7/30/2015)... N.J. , July 30, 2015 Eisai ... in the United States , European ... FDA, EMA and MHLW, respectively) for eribulin, for the ... who have received prior chemotherapy for advanced or metastatic ... on data from a pivotal global Phase 3 clinical ...
Breaking Medicine Technology:Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 2Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 3Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 4Eisai Submits Simultaneous Regulatory Applications for Eribulin in Soft Tissue Sarcoma in the United States, European Union and Japan 5
... YORK, Jan. 13, 2011 Reportlinker.com announces that ... its catalogue: Merck & Co., ... IntroductionThis analysis examines the ... in the prescription pharmaceutical sector. The profile encompasses ...
... Codexis, Inc. (Nasdaq: CDXS) today announced the company will host ... at 4:30 p.m. Eastern Time to discuss its fourth quarter ... call and webcast will follow the release of fourth quarter ... call will be available approximately one hour after the call ...
Cached Medicine Technology:Reportlinker Adds Merck & Co., Inc.: PharmaVitae Profile 2
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on ... and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the ... allows users to clarify, edit and delete any message including ones already sent. , ...
(Date:7/31/2015)... Ind. (PRWEB) , ... August 01, 2015 , ... The ... the Global Advisory Panel on the Future of Nursing (GAPFON) 20-21 July 2015 in ... invited to participate in this meeting. , Dr. Silvia Cassiani, Advisor, Nursing and Allied ...
(Date:7/31/2015)... ... July 31, 2015 , ... ... run by GoodThreads. The store can be accessed by visiting http://www.curemeso.org/store . ... which are customizable. The best part: whenever a product is purchased, the Meso ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin ... re-branded their social media profiles to better connect with the public. The agency ... find information, share insights and opinions. The Rally Insurance Group, Inc.’s pledge to ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article ... see if they could reach a consensus on the steps that need to be ... the group reached 90 percent consensus on a series of steps that each surgeon ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... Growth Initiatives, ROCHESTER, N.Y., Sept. 17 ... completed a private placement of,$4,350,000 of Series B ... institutional and other accredited investors. VirtualScopics,currently intends to ... expand its,sales and marketing efforts, software and technology ...
... Sept. 17 CryoCor, Inc. (Nasdaq:,CRYO), a medical device ... that Edward F. Brennan, President and Chief,Executive Officer, and ... at the Maxim Group First Annual Growth Conference in,New ... a.m. ET at The Grand,Hyatt Hotel. A live ...
... St. Margaret,s Daughters, Home, NEW ORLEANS, Sept. 17 ... New Orleans will be reunited in a,temporary facility this ... Hurricane Katrina. The 116-bed eldercare facility was destroyed ... Ninth Ward. While everyone at St.,Margaret,s was evacuated safely ...
... John Brooke, General Manager of,Billian,s HealthDATA, leading provider ... ,07 Global Gathering, Salesforce.com,s 5th,Annual User and Developer ... is the ultimate gathering of the salesforce.com community,bringing ... and AppExchance,users spanning industries, roles and locales. Mr. ...
... time scientists have been able to film, in real ... DNA strand from an attacking virus. Researchers from the ... Force Microscope in Japan to produce amazing footage of ... trying to infect a bacterial host. , The ...
... may only be modestly accurate, according to researchers from the ... Carolina. In a study that appears in the October issue ... usefulness of a scale that asks patients in primary care ... 10 (worst pain). , Universal pain screening is ...
Cached Medicine News:Health News:VirtualScopics Announces $4.35 Million Private Placement 2Health News:VirtualScopics Announces $4.35 Million Private Placement 3Health News:CryoCor to Present at Maxim Group First Annual Growth Conference in New York 2Health News:Renovated New Orleans Care Facility Reopens, Reuniting Residents and Staff 2Health News:Renovated New Orleans Care Facility Reopens, Reuniting Residents and Staff 3Health News:Billian's HealthDATA GM Speaking on Dreamforce 07 Panel 2Health News:Scientists reveal DNA-enzyme interaction with first ever real time footage 2Health News:Rating your pain from 0 to 10 might not help your doctor 2
Simply stated, no bone cement can match the history of Simplex™. Simplex™ is the only cement with 40 years of proven clinical performance - trusted by tens of thousands of surgeons with o...
DePuy 2 Bone Cement is a unique fast-set digital cement that is the excellent choice for small joint procedures such as the patella, glenoid or other extremity joints....
... John Charnley and CMW, Inc. began ... bone cements exclusively for orthopaedic applications. ... years of performance and excellence in ... one of the first proven bone ...
... Paradigm's Dicon Ocular Blood Flow Analyzer is ... increase your early diagnosis of low and ... (BFA) provides a fast, clinically proven measurement ... BFA assists in the management of glaucoma, ...
Medicine Products: